University Of Medicine And Dentistry Of New Jersey
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.umdnj.edu/
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Biological: therapeutic allogeneic lymphocytes
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-11-06
- Target Recruit Count
- 37
- Registration Number
- NCT00161187
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
Withdrawn
- Conditions
- Prostate Cancer
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Acitretin and Etanercept in Psoriasis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-02-16
- Target Recruit Count
- 10
- Registration Number
- NCT00156247
Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 44
- Registration Number
- NCT00161213
- Locations
- ๐บ๐ธ
Central Jersey Oncology Group, New Brunswick, New Jersey, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
๐บ๐ธCentraState Medical Center, Freehold, New Jersey, United States
Alefacept Mechanism of Action in Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-08-07
- Target Recruit Count
- 9
- Registration Number
- NCT00150982
- Locations
- ๐บ๐ธ
UMDNJ Clinical Research Center, New Brunswick, New Jersey, United States
Bexarotene With Narrow-Band UVB for Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-08-07
- Target Recruit Count
- 35
- Registration Number
- NCT00151008
Efalizumab for Eczema
Phase 2
Completed
- Conditions
- Dermatitis, Atopic
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-08-07
- Target Recruit Count
- 10
- Registration Number
- NCT00146003
- Locations
- ๐บ๐ธ
UMDNJ Psoriasis Center of Excellence, New Brunswick, New Jersey, United States
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
Phase 2
Terminated
- Conditions
- EczemaPsoriasis
- Interventions
- Drug: Neuroskin ForteDrug: Placebo Application
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-04-25
- Target Recruit Count
- 13
- Registration Number
- NCT00143819
Transitioning From Cyclosporine to Alefacept in Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2009-01-05
- Target Recruit Count
- 13
- Registration Number
- NCT00143806
- Locations
- ๐บ๐ธ
UMDNJ Clinical Research Center, New Brunswick, New Jersey, United States
Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers
Completed
- Conditions
- Heart RateBlood Pressure
- Interventions
- Behavioral: Treadmill testingBehavioral: Ambulatory Blood Pressure and Heart Rate Monitoring
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2009-08-24
- Target Recruit Count
- 36
- Registration Number
- NCT00143988
- Locations
- ๐บ๐ธ
Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath